Management Team

Screen Shot 2020-03-10 at 6.44.15 PM.png

Jarrett Duncan

Chief Executive Officer & General Counsel

Mr. Duncan co-­founded RS Oncology in 2017 in collaboration with an academic laboratory which made the underlying scientific discovery. Mr. Duncan’s previously practiced in a large New England law firm and lead an acquisitions team for a large insurance company. He also has significant experience in developing successful innovative technologies to combat air and water pollution. Mr. Duncan is a graduate of the University of Massachusetts, Amherst and Vermont Law School and is a licensed attorney in Massachusetts and New Hampshire.

George Naumov, Ph.D.

Chief Operations Officer & Head of Business Development

Dr. George Naumov is the COO and Head of Business Development at RS Oncology. Dr. Naumov was previously the head of Clinical Science at Karyopharm Therapeutics Inc, Newton MA. He was involved with the development and approval of Selinexor (Xpovio), a first in class SINE XPO1 antagonist. Dr. Naumov was a management consultant with the DavCard Group and MedPharma Partners and has over 15 years of pharma/biotech consulting experience. He was a co­founder, President & CEO of Zateras Therapeutics Inc., a Boston­ based startup.  Previously he was a Sr. Research Biologist in Oncology at Merck & Co and a scout for Merck Venture Fund.  He holds a B.Sci. (Hon.) in biochemistry from Queen’s University at Kingston and a Ph.D. in Medical Biophysics from the University of Western Ontario, Canada. He ran a laboratory under Dr. Judah Folkmans at Harvard Medical School and Children’s Hospital Boston. He is widely published in the field of oncology. During his career, George has built a scientific and business brand of collaboration and innovation, both in academic and commercial settings.